CCN on MSN52m
SEC’s Free Rein in Question as Probes Now Need Higher-Level Approval
The SEC must now seek approval before launching investigations. Previously, the enforcement division had more autonomy in ...
Q4 2024 IDEXX Laboratories Inc Earnings Call
Jonathan Block; Analyst; Stiefel Laboratories Inc Navann Ty Dietschi; Analyst; BNP Paribas Exane ...
JD Supra14h
Defense Contractor Resolves DOJ and SEC FCPA, FCA, Export Controls Violations for $950 Million
In October 2024, the Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) announced settlements with Raytheon Company, ...
JD Supra14h
Current Developments in SEC Enforcement for Public Companies and a Look Ahead 2024–2025
The US Securities and Exchange Commission (SEC) brought a number of notable enforcement proceedings against public companies in fiscal year ...
IDEXX Laboratories, Inc. (IDXX) Q4 2024 Earnings Call Transcript
IDEXX Laboratories, Inc. ( NASDAQ: IDXX) Q4 2024 Earnings Conference Call February 3, 2025 8:30 AM ET Brian McKeon - Chief Financial Officer Andrew Emerson - Senior Vice President, Corporate & ...
IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results. "IDEXX had a solid ...
manilatimes21h
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...
SC House GOP stops short of calling on Loftis to leave after $1.8B error. Here’s why
Despite a hostile exchange between Treasurer Curtis Loftis and a panel of House budget writers over a $1.8 billion accounting ...